Is Compounded Semaglutide Available in 2026

Introduction

Yes. Compounded semaglutide is still available in 2026 through state-licensed 503A pharmacies prescribing for patient-specific clinical needs. The 503B shortage-based bulk compounding window closed in 2025, so the supply landscape is narrower than during 2023-2024, but the door isn’t shut.

The FDA declared the semaglutide shortage resolved in February 2025. After that resolution, 503B outsourcing facilities can no longer mass-produce compounded copies under the shortage exemption. 503A pharmacies operating under state pharmacy boards continue to compound for individual prescriptions documenting clinical reasons the commercial product can’t meet.

This piece covers what changed, what’s still legal, what the lawsuits did, and how to get compounded semaglutide in 2026 without ordering from a sketchy site.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What’s the Current FDA Status of Semaglutide Compounding?

The FDA placed semaglutide on its Drug Shortage List in 2022. While on the list, 503B outsourcing facilities could compound bulk copies for distribution. The FDA removed semaglutide from the shortage list on February 21, 2025, ending that exemption.

Quick Answer: FDA resolved the semaglutide shortage February 21, 2025; 503B compounding under shortage exemption ended that date

Section 503A of the FD&C Act remains the legal basis for patient-specific compounding. Under 503A, a state-licensed pharmacy can compound a non-commercial formulation for an individual patient with a valid prescription, when the prescribing provider determines the commercial product doesn’t meet that patient’s clinical need.

Is 503A Compounding Still Allowed for Semaglutide?

Yes, under specific conditions. The pharmacy must be state-licensed. The prescription must be patient-specific (not anticipatory). The formulation must differ in a clinically meaningful way from the commercial product (different concentration, different dosage form, removal of an excipient the patient can’t tolerate, or addition of an excipient like B12 for a clinical reason).

Telehealth platforms working with 503A pharmacies in 2026 document those clinical reasons in patient files. Failure to document is the most common path to enforcement.

What Changed After the Shortage Resolution?

Three things. First, bulk 503B production for non-specific patient pools ended. Second, several large compounders pivoted to tirzepatide only (which was on shortage longer) or exited GLP-1 compounding. Third, prices stabilized at the $199-$399 monthly range from quality 503A operators.

The cheapest bulk sellers, often pricing semaglutide at $99-$149, mostly disappeared in 2025 because they couldn’t operate under 503A rules on per-patient documentation.

What Did the Lilly and Novo Lawsuits Do?

Novo Nordisk filed lawsuits in 2024 against compounding pharmacies and telehealth companies it said were misbranding compounded semaglutide or operating outside 503A bounds. Some defendants settled, some ceased operations, and some continue to litigate.

The lawsuits accelerated the cleanup of the market. Operators with documented 503A protocols, US-licensed pharmacists, and proper API sourcing kept operating. Operators relying on the shortage exemption or selling from overseas-style “research peptide” channels mostly exited.

Who Can Prescribe Compounded Semaglutide in 2026?

Any licensed prescriber (MD, DO, NP, PA) with prescriptive authority in the patient’s state can prescribe. Telehealth platforms employ providers who do video visits and write prescriptions to partner 503A pharmacies. State telehealth and pharmacy laws apply, so the available platforms vary by state.

Some states (California, Florida, New York, Texas) have the broadest availability. A few states have tighter restrictions on compounding for non-resident patients.

How Do You Find a Legitimate Compounder?

Three checks. Verify the pharmacy is listed in the NABP (National Association of Boards of Pharmacy) Verified Pharmacy Program or licensed in your state. Confirm the prescriber is licensed in your state via the state medical board. Ask the pharmacy for a certificate of analysis (COA) on a recent batch.

Red flags include no pharmacy address listed, no licensed pharmacist named, prices below $150 per month sustained, and any product labeled “research only” or “not for human use.”

Is TrimRx Still Selling Compounded Semaglutide?

Yes. TrimRx works with US-licensed 503A pharmacies and licensed prescribers. The free assessment quiz screens for medical eligibility, contraindications, and patient-specific factors. A personalized treatment plan documents the clinical rationale required for 503A compounding.

Compounded semaglutide pricing on TrimRx tracks the broader market range. The platform doesn’t undercut quality by sourcing from unverified channels.

Key Takeaway: Lilly and Novo lawsuits in 2024-2025 forced bulk compounders to exit; quality 503A operators continue

How Does This Compare to Ozempic® and Wegovy® Availability?

Ozempic (semaglutide for type 2 diabetes) and Wegovy (semaglutide for weight loss) are widely available in 2026 now that the shortage resolved. Insurance covers Ozempic for diabetes broadly; Wegovy coverage for weight loss varies by plan and increasingly requires step therapy.

Brand list prices are roughly $1,000-$1,400 per month. Novo’s NovoCare self-pay program offers Wegovy at about $499/month for some patients. Compounded prices remain meaningfully lower for uninsured weight-loss patients.

What About State-level Restrictions?

Mississippi, Louisiana, and a handful of other states tightened compounding rules in 2024-2025, requiring stricter documentation or specific in-state prescriber relationships. Some telehealth providers don’t offer compounded GLP-1 in those states.

Always check what’s available in your state at the assessment stage rather than assuming. The TrimRx assessment includes state-specific eligibility.

Is the Price the Same as 2024?

Lower for high-quality pharmacies, higher for bottom-tier. The bulk-discount channels at $99-$149 mostly closed. The mid-quality and premium channels stabilized at $199-$399. Mounjaro® and Ozempic brand pricing crept down via direct-to-patient programs but is still well above compounded.

A reasonable expectation in 2026 is $250-$350 monthly for compounded semaglutide from a quality 503A operator.

What Happens If Semaglutide Returns to Shortage?

Unlikely in 2026 given expanded Novo manufacturing capacity. If a regional shortage occurred, 503B bulk compounding could resume under the shortage exemption for that period. The FDA actively monitors the list.

503A patient-specific compounding doesn’t depend on shortage status, so it continues regardless.

What Dose Forms Are Available Compounded?

Most compounded semaglutide ships as a multi-dose vial with a separate vial of bacteriostatic water for reconstitution. Patients self-inject with insulin syringes (29-31G, 5/16-inch). Some compounders ship prefilled syringes or pen-like devices.

Concentrations vary. Common is 2.5mg/ml or 5mg/ml semaglutide. The titration schedule mirrors Wegovy: 0.25mg week 1-4, 0.5mg week 5-8, 1.0mg week 9-12, 1.7mg week 13-16, 2.4mg maintenance.

What About Combo Formulations?

Compounded semaglutide with B12, with glycine, with NAD+, or with a lipotropic complex (Lipo-C) are all available from various pharmacies. None of those combinations are FDA-approved. The clinical evidence for added benefit beyond the GLP-1 alone is limited.

For most patients, plain compounded semaglutide is appropriate. Combos make sense when there’s a clinical reason (documented B12 deficiency, for example).

Bottom line: STEP 1 (Wilding et al. 2021 NEJM) showed 14.9% mean weight loss at 68 weeks on injectable semaglutide

FAQ

Is Compounded Semaglutide Legal in 2026?

Yes, when prescribed by a licensed provider and dispensed by a state-licensed 503A pharmacy for a patient-specific clinical need. 503B shortage-based compounding ended February 2025 when the FDA resolved the semaglutide shortage.

How Much Does Compounded Semaglutide Cost in 2026?

$199-$399 per month from quality 503A operators is the typical range. Prices below $150 sustained should be questioned about sourcing. Prices above $500 are above market.

Why Did Some Telehealth Companies Stop Selling Compounded Semaglutide?

When the FDA resolved the semaglutide shortage in February 2025, the 503B bulk compounding exemption ended. Companies relying on bulk supply without per-patient 503A documentation lost their pipeline.

Can My Doctor Prescribe Compounded Semaglutide?

Yes, if your state allows compounded GLP-1 prescribing and your doctor has prescriptive authority. Telehealth platforms make this easier by employing licensed providers and partnering with 503A pharmacies.

Is Compounded Semaglutide as Effective as Wegovy?

The molecule is the same. Trial data on injectable semaglutide (STEP 1, 14.9% loss at 68 weeks) applies to the active drug. Real-world outcomes depend on dose, adherence, and pharmacy quality.

What’s the Difference Between 503A and 503B Compounding?

503A is patient-specific compounding by state-licensed pharmacies for individual prescriptions. 503B is bulk outsourcing facility compounding under FDA cGMP oversight, allowed without patient-specific scripts during drug shortages.

How Do I Know If a Pharmacy Is Legitimate?

Check NABP Verified Pharmacy Program listing, state pharmacy board licensing, and request a recent batch certificate of analysis. A real pharmacy has a physical address, a named pharmacist-in-charge, and US state licensing.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.